Mr. Michael Zhao is CEO of DiNovA Medtech, specializing in investing in and bringing innovative medical technologies to China, including Vessix, LoneStar, Broncus and Venus. Prior to that, Michael was the Executive Director and CEO of Lifetech Scientific. During his tenure (2010-15), the company went public in Hong Kong with an enhanced valuation of up to 40 folds due to his vision to lead and orchestrate a strategic partnership between Lifetech and Medtronic that became a global benchmark for international collaboration. Michael started his career in medical device with Johnson & Johnson’s Cordis division in 1998, and took on global leadership positions of increasing responsibility, including Global Product Strategy (USA), European Product Manager (Belgium), Group Marketing Manager (Australia & New Zealand) and General Manager (China).
Michael is an active contributing member to China’s healthcare industry. He is co-founder and co-chairman of the China Innovation in Cardiology conference (CIC); co-Director of the CV Engineering Center of Jiang Su Provincial Hospital and executive member of the Society of Pediatric Cardiology, Pacing &EP Society, Biomaterials Society and the Association of Medical Device Industry. He is also an active board member of seven medical device companies.
Michael has a BSc degree from Huntington College (USA), MBA from the University of Western Ontario (Canada) and studied at Leeds University (England) and Fudan University (Shanghai).